<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05107557</url>
  </required_header>
  <id_info>
    <org_study_id>PRO-nCOV-4002-1</org_study_id>
    <nct_id>NCT05107557</nct_id>
  </id_info>
  <brief_title>Immunogenicity And Safety of COVID-19 Vaccine , Inactivated Co -Administration With EV71 Vaccine (Vero Cell)</brief_title>
  <official_title>A Randomized and Controlled Phase IV Clinical Trial to Evaluate the Immunogenicity and Safety of COVID-19 Vaccine (Vero Cell), Inactivated Co-administrated With EV71 Vaccine (Vero Cell) in Children Aged 3-5 Years Old</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sinovac Biotech Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sinovac Biotech Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized and controlled Phase IV clinical trial of the COVID-19 vaccine&#xD;
      (Vero cell), Inactivated manufactured by Sinovac Research &amp; Development Co., Ltd. The purpose&#xD;
      of this study is to evaluate the immunogenicity and safety of COVID-19 vaccine (Vero cell),&#xD;
      Inactivated co-administration with EV71 vaccine&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized and controlled phase IV clinical trial in children aged 3-5 years&#xD;
      old. The purpose of this study is to evaluate the immunogenicity and safety of COVID-19&#xD;
      vaccine (Vero cell), Inactivated co-administration with EV71 vaccine.The COVID-19 vaccine was&#xD;
      manufactured by Sinovac Research &amp; Development Co., Ltd and the EV71 vaccine was manufactured&#xD;
      by Sinovac Biotech Co.A total of 520 subjects aged 3-5 years old will be enrolled.Subjects&#xD;
      will be randomly divided into 2 groups in a ratio of 1:1.The experimental group is the&#xD;
      combined immunization group, which will receive the first dose of COVID-19 vaccine and the&#xD;
      first dose of EV71 vaccine on day 0 and the second dose of COVID-19 vaccine and EV71 vaccine&#xD;
      on day 28;Control group is the Non-combined immunization group , which will receive the first&#xD;
      dose of COVID-19 vaccine on day 0 ,the first dose of EV71 vaccine on day 14, the second dose&#xD;
      of COVID-19 vaccine on day 28 and the second dose of EV71 vaccine on day 42.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 5, 2021</start_date>
  <completion_date type="Anticipated">May 5, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 5, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immunogenicity index-Seroconversion rate of the neutralizing antibody to live SARS-CoV-2</measure>
    <time_frame>Day 28 after the second dose of COVID-19 vaccine</time_frame>
    <description>Seroconversion rate of the neutralizing antibody to live SARS-CoV-2 at day 28 after the second dose of COVID-19 vaccine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity index-Seroconversion rate of the neutralizing antibody to EV71</measure>
    <time_frame>Day 28 after the second dose of EV71 vaccine</time_frame>
    <description>Seroconversion rate of the neutralizing antibody to EV71 at day 28 after the second dose of EV71 vaccine</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity index-Seropositivity rate of the neutralizing antibody to live SARS-CoV-2</measure>
    <time_frame>Day 28 after the second dose of COVID-19 vaccine</time_frame>
    <description>Seropositivity rate of the neutralizing antibody to live SARS-CoV-2 at day 28 after the second dose of COVID-19 vaccine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity index- GMT of the neutralizing antibody to live SARS-CoV-2</measure>
    <time_frame>Day 28 after the second dose of COVID-19 vaccine</time_frame>
    <description>GMT of the neutralizing antibody to live SARS-CoV-2 at day 28 after after the second dose of COVID-19 vaccine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity index-GMI of the neutralizing antibody to live SARS-CoV-2</measure>
    <time_frame>Day 28 after the second dose of COVID-19 vaccine</time_frame>
    <description>GMI of the neutralizing antibody to live SARS-CoV-2 at day 28 after after the second dose of COVID-19 vaccine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity index-Seropositive rate of the neutralizing antibody to EV71</measure>
    <time_frame>Day 28 after the second dose of EV71</time_frame>
    <description>Seropositive rate of the neutralizing antibody to EV71 at day 28 after the second dose of EV71</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity index-GMT of the neutralizing antibody to EV71</measure>
    <time_frame>Day 28 after the second dose of EV71</time_frame>
    <description>GMT of the neutralizing antibody to EV71 at day 28 after the second dose of EV71</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity index-GMI of the neutralizing antibody to EV71</measure>
    <time_frame>Day 28 after the second dose of EV71</time_frame>
    <description>GMI of the neutralizing antibody to EV71 at day 28 after the second dose of EV71</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety index-Incidence of the adverse reactions</measure>
    <time_frame>From day 0 to day 7 after each dose</time_frame>
    <description>Incidence of the adverse reactions from day 0 to day 7 after each dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety index-Incidence of the adverse reactions</measure>
    <time_frame>From day 0 to 28 days after the last dose</time_frame>
    <description>Incidence of the adverse reactions from day 0 to 28 days after the last dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety index-Incidence of the serious adverse events and the adverse events of special concern</measure>
    <time_frame>From the beginning vaccination to 6 months after the last dose</time_frame>
    <description>Incidence of the serious adverse events and the adverse events of special concern from the beginning vaccination to 6 months after the last dose</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Immunogenicity index-Seropositive rate of the neutralizing antibody to live SARS-CoV-2</measure>
    <time_frame>6 months after the second dose of COVID-19 vaccine</time_frame>
    <description>Seropositive rate and GMT of the neutralizing antibody to live SARS-CoV-2 6 months after the second dose of COVID-19 vaccine</description>
  </other_outcome>
  <other_outcome>
    <measure>Immunogenicity index- GMT of the neutralizing antibody to live SARS-CoV-2</measure>
    <time_frame>6 months after the second dose of COVID-19 vaccine</time_frame>
    <description>GMT of the neutralizing antibody to live SARS-CoV-2 6 months after the second dose of COVID-19 vaccine</description>
  </other_outcome>
  <other_outcome>
    <measure>Immunogenicity index-Seropositive rate of the neutralizing antibody to EV71</measure>
    <time_frame>6 months after the second dose of EV71 vaccine</time_frame>
    <description>Seropositive rate of the neutralizing antibody to EV71 6 months after the second dose of EV71 vaccine</description>
  </other_outcome>
  <other_outcome>
    <measure>Immunogenicity index-GMT of the neutralizing antibody to EV71</measure>
    <time_frame>6 months after the second dose of EV71 vaccine</time_frame>
    <description>GMT of the neutralizing antibody to EV71 6 months after the second dose of EV71 vaccine.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">520</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Experimental Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The experimental group is also called the combined immunization group.260 participants will receive the first dose of COVID-19 vaccine and EV71 vaccine on day 0 and the second dose of COVID-19 vaccine and EV71 vaccine on day 28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The control group is also called the Non-combined immunization group.260 participants will receive the first dose of COVID-19 vaccine on day 0,the first dose of EV71 vaccine on day 14,the second dose of COVID-19 vaccine on day 28 and the second dose of EV71 vaccine on day 42.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Experimental Group</intervention_name>
    <description>The COVID-19 vaccine was manufactured by Sinovac Research &amp; Development Co., Ltd, and the EV71 vaccine was manufactured by Sinovac Biotech Co.The COVID-19 vaccine:600SU inactivated virus in 0.5mL of aluminium hydroxide solution per injection;The EV71 vaccine:Inactivated EV71 virus antigen no less than 3.0EU in 0.5 mL of aluminium hydroxide solution per injection.</description>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>Experimental Group</arm_group_label>
    <other_name>Combined immunization group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Children aged 3-5 years;&#xD;
&#xD;
          -  The subject and/or guardian can understand and voluntarily sign the informed consent&#xD;
             form;&#xD;
&#xD;
          -  Proven legal identity.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of contact with a SARS-CoV-2 infection (positive in nucleic acid test) within&#xD;
             14 days;&#xD;
&#xD;
          -  History of multiple system inflammatory syndrome (MIS-C);&#xD;
&#xD;
          -  History of hand, foot and mouth disease, herpetic angina or EV71 vaccination;&#xD;
&#xD;
          -  History of asthma, history of allergy to the vaccine or vaccine components,or serious&#xD;
             adverse reactions to the vaccine, such as urticaria, dyspnea,and angioedema;&#xD;
&#xD;
          -  Congenital malformations or developmental disorders, genetic defects,severe&#xD;
             malnutrition, etc.;&#xD;
&#xD;
          -  Autoimmune disease (Systemic lupus erythematosus)or immunodeficiency /&#xD;
             immunosuppression(HIV,history after organ transplantation);&#xD;
&#xD;
          -  Severe chronic diseases, severe cardiovascular diseases, hypertension and diabetes&#xD;
             that cannot be controlled by drugs, liver or kidney diseases,malignant tumors, etc.;&#xD;
&#xD;
          -  Severe neurological disease (epilepsy, convulsions or convulsions) or mental illness;&#xD;
&#xD;
          -  Thyroid disease or history of thyroidectomy, asplenia,functional asplenia, asplenia or&#xD;
             splenectomy resulting from any condition;&#xD;
&#xD;
          -  Diagnosed abnormal blood coagulation function (eg, lack of blood coagulation factors,&#xD;
             blood coagulopathy,abnormal platelets) or obvious bruising or blood coagulation;&#xD;
&#xD;
          -  Immunosuppressive therapy, cytotoxic therapy, inhaled corticosteroids (excluding&#xD;
             allergic rhinitis corticosteroid spray therapy, acute noncomplicated dermatitis&#xD;
             superficial corticosteroid therapy) in the past 6 months;&#xD;
&#xD;
          -  History of drug abuse;&#xD;
&#xD;
          -  Receipt of blood products within in the past 3 months;&#xD;
&#xD;
          -  Receipt of other investigational drugs in the past 30 days;&#xD;
&#xD;
          -  Receipt of attenuated live vaccines in the past 14 days;&#xD;
&#xD;
          -  Receipt of inactivated or subunit vaccines in the past 7 days;&#xD;
&#xD;
          -  Severe neurological disease (epilepsy, convulsions or convulsions) or mental illness;&#xD;
&#xD;
          -  Axillary temperature &gt;37.0Â°C;&#xD;
&#xD;
          -  The subjects participated in other clinical trials during the follow-up period,or will&#xD;
             be planned within 3 months;&#xD;
&#xD;
          -  According to the investigator's judgment, the subject has any other factors that are&#xD;
             not suitable for participating in the clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhuhang Huang, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangdong Center for Disease Prevention and Control</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhuhang Huang, Master</last_name>
    <phone>13602438596</phone>
    <email>gdswyw_sps@cdcp.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yangchun City Center for Disease Control and Prevention</name>
      <address>
        <city>Yangchun</city>
        <state>Guangdong</state>
        <zip>529699</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yebin Yu</last_name>
      <phone>13829891118</phone>
      <email>951421697@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhanjiang Center for Diseases Control and Prevention</name>
      <address>
        <city>Zhenjiang</city>
        <state>Guangdong</state>
        <zip>524005</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Huangsheng Pan</last_name>
      <phone>18902578390</phone>
      <email>562007632@qq.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 2, 2021</study_first_submitted>
  <study_first_submitted_qc>November 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2021</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

